New HIV/AIDS study findings have been reported from National Institutes of Health
2009 JUL 8 - (NewsRx.com) -- "Using 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one and 4,5-dihydroxy-1H-isoindole-1,3(2H)-dione based HIV-1 integrase inhibitors as display platforms, we undertook a thorough examination of the effects of modifying the halogen substituents on a key benzyl ring that is hypothesized to bind in a hydrophobic pocket of the integrase. DNA complex," scientists in the United States report. "Data from this study suggest that in general dihalo-substituted analogues have higher potency than monohalo-substituted compounds, but that further addition of halogens is not beneficial," wrote X.Z. Zhao and colleagues, National Institutes of Health. The researchers concluded: "Published by Elsevier Ltd.." Zhao and colleagues published their study in Bioorganic & Medicinal Chemistry Letters (Examination of halogen substituent effects on HIV-1 integrase inhibitors derived from 2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-ones and 4,5-dihydroxy-1H-isoindole-1,3(2H)-diones. Bioorganic & Medicinal Chemistry Letters, 2009;19(10):2714-2717). For additional information, contact T.R. Burke, National Cancer Institute, Medical Chemical Laboratory, Center Cancer Research, National Institutes of Health, Frederick, MD 21702, USA. The publisher's contact information for the journal Bioorganic & Medicinal Chemistry Letters is: Pergamon-Elsevier Science Ltd., the Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, England. Keywords: United States, Frederick, HIV/AIDS, AIDS, Acquired Immunodeficiency Syndrome, Enzymology, HIV, Human Immunodeficiency Virus, Integrase, Medicinal Chemistry, Virology, National Institutes of Health. This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2009, Immunotherapy Weekly via NewsRx.com.
|
